Vaxcyte, Inc. (MUN:5VA)
Germany
· Delayed Price · Currency is EUR 51.50
+11.50 (28.75%)
At close: Mar 9, 2026
Vaxcyte Statistics
Total Valuation
Vaxcyte has a market cap or net worth of EUR 7.33 billion. The enterprise value is 6.10 billion.
| Market Cap | 7.33B |
| Enterprise Value | 6.10B |
Important Dates
The next estimated earnings date is Thursday, May 7, 2026.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 143.92M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +11.55% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 0.67% |
| Owned by Institutions (%) | 96.05% |
| Float | 132.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.20 |
| P/TBV Ratio | 3.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.34 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.04 |
Financial Position
The company has a current ratio of 7.91, with a Debt / Equity ratio of 0.04.
| Current Ratio | 7.91 |
| Quick Ratio | 7.81 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.16 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -25.59% and return on invested capital (ROIC) is -18.68%.
| Return on Equity (ROE) | -25.59% |
| Return on Assets (ROA) | -17.72% |
| Return on Invested Capital (ROIC) | -18.68% |
| Return on Capital Employed (ROCE) | -33.02% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.29M |
| Employee Count | 507 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.00% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -49.00% |
| 50-Day Moving Average | 46.28 |
| 200-Day Moving Average | 29.51 |
| Relative Strength Index (RSI) | 53.78 |
| Average Volume (20 Days) | 146 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 10.27 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -786.69M |
| Pretax Income | -652.94M |
| Net Income | -652.94M |
| EBITDA | -772.73M |
| EBIT | -786.69M |
| Earnings Per Share (EPS) | -4.80 |
Balance Sheet
The company has 1.33 billion in cash and 100.06 million in debt, giving a net cash position of 1.23 billion.
| Cash & Cash Equivalents | 1.33B |
| Total Debt | 100.06M |
| Net Cash | 1.23B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 2.29B |
| Book Value Per Share | 17.45 |
| Working Capital | 1.21B |
Cash Flow
In the last 12 months, operating cash flow was -558.35 million and capital expenditures -48.52 million, giving a free cash flow of -606.88 million.
| Operating Cash Flow | -558.35M |
| Capital Expenditures | -48.52M |
| Depreciation & Amortization | 14.02M |
| Net Borrowing | n/a |
| Free Cash Flow | -606.88M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vaxcyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.55% |
| Shareholder Yield | -11.55% |
| Earnings Yield | -8.91% |
| FCF Yield | -8.28% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |